Alnylam Pharmaceuticals Inc (ALNY) Insider Trading
- $71,277,732.32
- $464,925,039.46
- March 3, 2026
- Akshay Vaishnaw
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| March 3, 2026 | EVP | 1,775 | $319.74 | Sell | $567,538.50 | |
| March 3, 2026 | EVP | 1,652 | $319.73 | Sell | $528,193.96 | |
| March 2, 2026 | EVP | 2,206 | $327.65 | Sell | $722,795.90 | |
| March 2, 2026 | EVP | 1,717 | $327.66 | Sell | $562,592.22 | |
| March 2, 2026 | EVP | 1,598 | $327.65 | Sell | $523,584.70 | |
| March 2, 2026 | CEO | 6,799 | $327.65 | Sell | $2,227,692.35 | |
| March 2, 2026 | EVP | 1,598 | $327.65 | Sell | $523,584.70 | |
| Feb. 17, 2026 | EVP | 2,041 | $331.96 | Sell | $677,530.36 | |
| Feb. 13, 2026 | EVP | 2,242 | $310.08 | Sell | $695,199.36 | |
| Feb. 13, 2026 | CEO | 6,958 | $310.08 | Sell | $2,157,536.64 | |
| Feb. 13, 2026 | EVP | 2,242 | $310.08 | Sell | $695,199.36 | |
| Feb. 13, 2026 | EVP | 1,959 | $310.08 | Sell | $607,446.72 | |
| Feb. 13, 2026 | EVP | 1,959 | $310.08 | Sell | $607,446.72 | |
| Sept. 9, 2025 | Director | 18,000 | $467.60 | Sell | $8,416,800.00 | |
| Aug. 19, 2025 | EVP | 1,455 | $458.41 | Sell | $666,986.55 | |
| Aug. 18, 2025 | CEO | 6,979 | $453.27 | Sell | $3,163,371.33 | |
| Aug. 18, 2025 | EVP | 1,396 | $453.27 | Sell | $632,764.92 | |
| Aug. 18, 2025 | Director | 11,250 | $450.00 | Sell | $5,062,500.00 | |
| Aug. 18, 2025 | EVP | 2,274 | $453.27 | Sell | $1,030,735.98 | |
| Aug. 18, 2025 | EVP | 1,396 | $453.27 | Sell | $632,764.92 | |
| Aug. 18, 2025 | EVP | 1,396 | $453.27 | Sell | $632,764.92 | |
| Aug. 14, 2025 | Director | 31,448 | $436.58 | Sell | $13,729,567.84 | |
| June 2, 2025 | CEO | 19,297 | $306.00 | Sell | $5,904,882.00 | |
| May 30, 2025 | CEO | 31,640 | $304.39 | Sell | $9,630,899.60 | |
| Feb. 18, 2025 | CMO | 1,548 | $251.67 | Sell | $389,585.16 | |
| Feb. 18, 2025 | EVP | 1,440 | $251.56 | Sell | $362,246.40 | |
| Feb. 14, 2025 | CMO | 1,561 | $255.17 | Sell | $398,320.37 | |
| Feb. 14, 2025 | CFO | 967 | $255.17 | Sell | $246,749.39 | |
| Feb. 14, 2025 | EVP | 663 | $255.21 | Sell | $169,204.23 | |
| Feb. 14, 2025 | CEO | 1,213 | $255.17 | Sell | $309,521.21 | |
| Jan. 27, 2025 | CMO | 52,592 | $285.00 | Sell | $14,988,720.00 | |
| Jan. 23, 2025 | Director | 11,250 | $275.00 | Sell | $3,093,750.00 | |
| Dec. 12, 2024 | CMO | 1,752 | $251.00 | Sell | $439,752.00 | |
| Nov. 26, 2024 | EVP | 1,469 | $250.98 | Sell | $368,689.62 | |
| Nov. 26, 2024 | CEO | 5,219 | $250.98 | Sell | $1,309,864.62 | |
| Nov. 26, 2024 | CMO | 1,682 | $250.98 | Sell | $422,148.36 | |
| Aug. 20, 2024 | CEO | 15,000 | $280.00 | Sell | $4,200,000.00 | |
| Aug. 6, 2024 | Director | 20,250 | $262.00 | Sell | $5,305,500.00 | |
| Aug. 1, 2024 | CEO | 15,148 | $270.00 | Sell | $4,089,960.00 | |
| July 11, 2024 | CEO | 7,093 | $261.00 | Sell | $1,851,273.00 | |
| June 25, 2024 | CEO | 8,301 | $230.99 | Sell | $1,917,447.99 | |
| June 25, 2024 | CMO | 2,103 | $230.99 | Sell | $485,771.97 | |
| June 25, 2024 | EVP | 1,198 | $230.99 | Sell | $276,726.02 | |
| June 25, 2024 | CFO | 1,605 | $231.00 | Sell | $370,755.00 | |
| June 24, 2024 | Director | 32,450 | $220.69 | Sell | $7,161,390.50 | |
| May 29, 2024 | Director | 21,700 | $148.60 | Sell | $3,224,620.00 | |
| Dec. 27, 2023 | Director | 30,000 | $195.00 | Sell | $5,850,000.00 | |
| Aug. 7, 2023 | CMO | 4,166 | $183.89 | Sell | $766,085.74 | |
| Aug. 4, 2023 | CEO | 4,057 | $185.85 | Sell | $753,993.45 | |
| Aug. 4, 2023 | CMO | 3,461 | $185.85 | Sell | $643,226.85 |
Insiders are both buying and selling Alnylam Pharmaceuticals Inc stock.
The insider traders at Alnylam Pharmaceuticals Inc are: John Maraganore, Akshay Vaishnaw, Yvonne Greenstreet, Pushkal Garg, Laurie Keating, Barry E Greene, Tolga Tanguler, Kevin Joseph Fitzgerald, Jeffrey V Poulton, Philip A Sharp, Michael Mason, Paul Schimmel, Dennis A Ausiello, Laurence Reid, Michael W Bonney, Sanofi, Steven M Paul, Kevin P Starr, Phillip A Sharp, Indrani Lall Franchini, David E I Pyott, Amy W Schulman, David-Alexandre C Gros, John Clarke, Kevin P. Starr, Marsha Fanucci, Philip A. Sharp, Phillip A. Sharp, and Colleen F Reitan
The most active insider trader at Alnylam Pharmaceuticals Inc is John Maraganore with 23 trades.
John Maraganore has sold the most Alnylam Pharmaceuticals Inc stock with a total value of $118,340,674.92.
Sanofi has bought the most Alnylam Pharmaceuticals Inc stock with a total value of $89,326,528.48.
The most recent insider trade for Alnylam Pharmaceuticals Inc was on March 3, 2026.
The single biggest insider buy for Alnylam Pharmaceuticals Inc was from Sanofi with a total value of $23,036,682.24 on March 25, 2014.
The single biggest insider sell for Alnylam Pharmaceuticals Inc was from Pushkal Garg with a total value of $14,988,720.00 on Jan. 27, 2025.
